Key Points – CARVYKTI sales surged in Q1 2026, with net trade sales of about $597 million, up 62% year over year.
Growth was driven by earlier-line use in the U.S. and strong international expansion, with ex-U.S. sales rising more than 200%. – Manufacturing execution improved but margins dipped due to one-time ramp costs at expanded facilities
Legend said gross margin was 41% in the quarter and expects it to rebound above 50% in Q2 as utilization improves. – Legend’s pipeline is advancing beyond CARVYKTI, especially its in vivo CAR T programs. The company said its BCMA and GPRC5D programs have entered Phase I, initial non-Hodgkin’s lymphoma data is expected this year, and it remains on track for 2026 profitability on an adjusted basis. – CPI Data Sparks Rally in Biotech Stocks Legend Biotech (NASDAQ:LEGN) reported sharply higher first-quarter 2026 sales for CARVYKTI, its CAR T therapy for multiple myeloma, as management said demand continued to move into earlier lines of treatment and international markets expanded. Chief Executive Officer Ying Huang said the company began 2026 with “strong momentum” commercially and in its pipeline.
He described Legend as “the largest standalone cell therapy company” and said CARVYKTI remains the company’s anchor product while it works to advance the therapy into the first-line treatment setting. – Why Legend Biotech Stock Is Having Its Best Month Yet CARVYKTI net trade sales were approximately $597 million in the first quarter, up 62% from the first quarter of 2025. Huang said U.S. sales grew 36% year over year, while ex-U.S. sales rose more than 200%. CARVYKTI Growth Driven by Earlier-Line Use Alan Bash, Legend’s President of CARVYKTI, said the therapy delivered 8% sequential growth from the fourth quarter of 2025.